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Thank you for giving us the opportunity to respond to the
comments by Philippe Poirson [1] on our study [2]. Al-
though the tone of unfounded reproach is, in our view, not
the way scientists should communicate and not helpful for
a scientific debate, we are grateful for being able to clarify
various issues that were mistakenly interpreted on several
occasions (see for example [3]).
First at all, C-SURF, the project from which our data for
the present study came, is funded by the Swiss National
Science Foundation, an independent organisation and not a
federal governmental agency. Thus, there is no federal sci-
ence muffling. Second, our results do not contain errors or
methodological biases, as we are reproached by Poirson,
nor is our conclusion “abusive” (although the language
used by Poirson is). Our conclusion states that WE found
no beneficial effects, and of course this refers only to OUR
study among young men. We are not claiming that there are
generally no beneficial effects in other studies all over the
world. Additionally, we cautiously chose this wording to
avoid saying that there were detrimental effects. This cau-
tious statement has also been commented on as an under-
statement of some actually negative effects [4]. We have
even discussed the potential for beneficial effects (e.g.,
more quit attempts) in our paper.
We are fully aware, on the one hand, that there is a heated
debate on e-cigarette use. On the other hand, Poirson
should also acknowledge that there are systematic reviews
confirming our findings [5, 6], although these have also
been criticised by those more in favour of vaping. Hence,
there is at least no unequivocal view about the effectiveness
of e-cigarettes for smoking cessation. The selective choice
of two, apparently real, longitudinal studies [7, 8] does not
dismiss our findings. We have never claimed that there can-
not be other studies with different findings. It is common
in research that not all studies converge on a unanimously
agreed finding. By the way, both "real" longitudinal stud-
ies used intensity/frequency measures of vaping measured
at follow-up only, something we have been criticised for
by Poirson. Additionally, Hitchman et al. [8] showed that
baseline vapers were less likely to quit smoking, although
not significantly so, but again at least no beneficial effect
of baseline vaping could be found. Most of the statements
made by Poirson are not comments on our study, but seem
to promote other studies with different findings and differ-
ent populations.
We have by no means tried to hide that vaping status was
not assessed at baseline. This was mentioned at several
places in our paper. However, this does not make our study
a cross-sectional study. We measured changes in smoking
status, and changes in number of cigarettes used between
baseline and follow-up. In addition, we do not think that
measuring vaping status at baseline would have changed
our results, as most participants were probably non-vapers
at baseline. As Kuendig et al. [9] have shown, e-cigarette
use more than doubled between 2013 and 2014/15. Given
this exponential growth (and we discussed other indicators
confirming such a growth), it is very unlikely that there
would have been many vapers at baseline (which was years
before 2013) and, thus, the large majority would have be-
come vapers between baseline and follow-up. Thus, we
mainly analysed whether those becoming vapers reduced
their use of cigarettes or stopped smoking compared with
those not becoming vapers. We acknowledge, however,
that this is not an optimal design. Nevertheless, we cannot
see how our finding can be interpreted in another way
than that vaping had no beneficial effect on conventional
smoking in a population of young men as a whole.
Our critic seems to make four fundamentally flawed pre-
suppositions:
a) that a study among young people has to support the
same conclusions as studies among older people or in
the general population at all ages;
b) that an epidemiological study on general use of e-cigar-
ettes must reach the same conclusions as smoking ces-
sation trials among heavy smokers;
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c) that data need to be broken down (heavy smokers that
at some point in time become daily vapers using 3rd
generation vaping tanks) until the desired effect is
found;
d) and that we should overload an article by plugging in
all the many analyses that he would like to see.
Young people may use e-cigarettes for reasons other than
long-time heavy smoking, such as for enjoyment, because
of curiosity, novelty, role modelling celebrities or just be-
cause it is fancy [10, 11]. For example, Saddleson et al. [11]
showed that young adults reported e-cigarettes use more
often for enjoyment reasons than for quitting smoking, as
opposed to older adults who often report using e-cigar-
ette to stop smoking. Moreover, Hitchman at al. study [8],
quoted by Poirson, showed that the 3rd generation tanks,
the more effective vaping tool for smoking cessation, were
most often used by older people and least by the young-
est. Thus, there may be differences between young vapers
and older long-term smokers, who more often may use vap-
ing for smoking cessation. Our study is an epidemiologic-
al study among young men. As shown by the Swiss mon-
itoring system [9] e-cigarette use is most prevalent among
the youngest (15–19 years old), and then strongly decreases
with age. If this age group is using e-cigarettes intermit-
tently (stated by Poirson to be 88%), why should we focus
our findings on the minority of daily users? Poirson accuses
us of hiding findings on daily use, but again, as rightly said
by Poirson, these findings were already published in 2013
[12] and we correctly referenced this study. Why should
we reproduce these findings again in a second article? We
do not think that these data have disappeared only because
they were not repeated. In addition, a secondary analys-
is of the more detailed data on daily vapers in our cohort
[12], which were also shown by Poirson on the webpage
Vapolitique [13] as a criticism (3 daily vapers among 22
ex-smokers; 27/222 among smokers), revealed that daily
vapers were not significantly more likely than nondaily
vapers (p = 0.841) to be ex-smokers. Moreover, as shown
in the original publication [12], no statistically significant
difference was found between daily vapers and non-vapers
in the number of cigarettes smoked per day, for the level
of nicotine dependence, and the number of quit attempts in
the past 12 months. Hence, again no beneficial effect was
found.
Poirson seems to want us to break down data until we find
a subgroup where vaping may have beneficial effects (e.g.,
heavily dependent smokers who are daily vapers using 3rd
generation kits). However, this does not reflect the situation
of current e-cigarette use among young Swiss men alto-
gether. Thus, we looked at the total population of young
male vapers, the way they are using e-cigarettes and the
generation of e-cigarettes that they were using. For this
representative sample of young Swiss men, we could not
find any beneficial effect of e-cigarette use overall. We do
not doubt that there could be beneficial effects of vaping
among some highly selective subsamples, but it seems not
to be the case for the large majority of young male vapers
in Switzerland. If we want to show the effect of alcohol use
on health overall, we would also not restrict the sample to
those drinking only 1 glass of wine every other day, be-
cause these particular alcohol users may be the most likely
to have overall beneficial outcomes on mortality and mor-
bidity as a result of cardioprotective effects.
Our study was not done to add to the two smoking cession
trials of the quoted Cochrane review [14], which, by the
way, drew very cautious conclusions from the two nonsig-
nificant studies included, nor can a single article fully cap-
ture all the analyses on social pressures, smoking relatives,
stigmatisation social-professional status, health status,
comparison of Swiss with foreigners, and concomitant use
of other psychoactive substances, suggested by Poirson. To
the best of our knowledge, we have not yet seen a single
article covering all these topics.
Poirson seems to criticise our sample because it consists of
only young men and therefore is biased. Well, it is true that
it consists of only young men, but there are many studies
on vaping using only subsamples of the total population.
Our sample covers 21 of 26 cantons and has a retention rate
of over 90%. It includes all sociodemographic subgroups
of men of this age and is therefore certainly less biased
for this population compared with well-affiliated college
samples. The study may also be less biased than studies,
obviously preferred by Poirson, with a follow-up of around
50%, such as the Biener and Hargraves [7] study, or even
less, as in the Hitchman et al. [8] study. Similarly, Etter
and Bullen’s [15] study described by Poirson as a “real
longitudinal study” reports lower response rates than C-
SURF (i.e., 62% for 1-month follow-up and 47% for 1-year
follow-up). Moreover, this study may also be subject to bi-
as because participants may have had special affinities for
e-cigarettes since they were enrolled on websites dedicated
to e-cigarettes and smoking cessation. This sample may be
biased because vapers not interested in stopping smoking
may be under-represented. Also, since the sample com-
prised vapers only, it was not possible to compare smoking
cessation rates between vapers and non-vapers.
Poirson seems to confuse selection bias with generalisation
to a larger population. However, our study is restricted to
young men. We cannot see that studies looking at sub-
samples such as young college students or school students
should be abandoned or are biased, because the sampling
frame is restricted, as long as they do not generalise find-
ings to all other parts of a population. We carefully dis-
cussed the point of having a bounded population and we
never claimed overarching conclusions or generalisations
to other segments of the population. We did not "evacuate"
health benefits of vaping compared with smoking, but
largely discussed this in the introduction, and we did not
give only one reference, but many. We clearly stated that
vaping is less harmful than smoking, but we did not analyse
all potential health benefits separately, and the paper was
not intended to analyse effects on asthma as suggested by
Poirson.
Poirson seems to be very concerned about the seeming pro-
hibition of vaping liquids. However there is no prohibi-
tion in Switzerland. It is legal to consume these liquids.
They can be bought across the border (and in Switzerland
nobody lives far away from borders) and they can also be
legally ordered via the internet. In fact, we even tested dir-
ect supply in Swiss shops. You can simply order e-liquids
via the internet, providing the mailing address of the shop.
The shops then “privately” exchange your ordered e-liquid
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arriving later with e-liquids from their existing “private”
stock. Nevertheless, we agree that this sale regulation may
limit the use of e-liquids with nicotine in Switzerland. Data
from the Swiss monitoring of addiction [16] showed that in
2013, only 29.7% of e-cigarette owners used nicotine e-li-
quids, but also that the prevalence of users of nicotine e-
liquids has increased since then [9]. Additionally, the be-
nefits of using nicotine e-liquid on smoking quitting and
reduction may not be as clear as suggested by Poirson. The
results of the Cochrane meta-analysis [14] cited by Poirson
to support his assertion are based on only two studies, both
yielding nonsignificant results when taken separately, and
the quality of evidence was rated as low. Moreover, when
discussing potential benefits for daily heavy smokers, one
may also wish to include potential harms by adding nicot-
ine via vaping among infrequent smokers or even non-
smokers, who are often not included in studies that follow
only heavy smokers who want to quit or reduce smoking
by means of vaping.
We will not discuss all the flaws included in the studies ref-
erenced by fact sheets, vaping lobbying pages or Power-
Point presentations, and we do not understand the connec-
tion with medically prescribed heroin substitution, which
was made available for dependent heroin users and had
no youth-oriented marketing. We are, however, clearly in
favour of prescribed nicotine replacement products, with
costs even being covered by health insurance in Switzer-
land. Such nicotine replacement might also include nicot-
ine liquids. We are also aware that future measurement in
C-SURF must be refined to include different generations
of e-cigarettes, nicotine-free versus nicotine-containing li-
quids, and motives to use these products. This is under way
with the 2nd follow-up of C-SURF, for which data collec-
tion has just started. We strongly protest against being por-
trayed by a vaping lobbyist as loyal assistants of official
federal science who are ideologically blind toward harm re-
duction strategies.
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